Skip to content
This GLP
Head to head

BioGlow Health vs PlushCare

The whole ladder published against a price that covers the starting dose.

By Dana SullivanEvidence reviewer

BioGlow Health

Editorial

$129/mo

BioGlow Health prices compounded semaglutide from $129 at 1 mg to $249 at 10 mg, and compounded tirzepatide from $169 at 10 mg to $299 at 60 mg, with a three-month bundle at $399 on either molecule. The whole ladder is printed beside the entry figure rather than revealed at the third refill. The bill therefore rises as the dose does, by a published amount.

Pick it for: Readers who want the escalation visible before enrolling

PlushCare

Editorial

$149/mo

PlushCare advertises compounded semaglutide at $149 a month cash-pay, and states that the figure buys the 0.25 mg starting dose only, with every maintenance dose priced higher. Compounded tirzepatide is $399. Insurance is accepted on a separate basis from either figure.

Pick it for: Readers who want an established clinical brand at the opening dose

Our verdict

BioGlow publishes its ladder in full. PlushCare prices the starting dose and says nothing about what follows. A reader can plan six months at one and only the first at the other.

What actually separates them

BioGlow Health and PlushCare state different things about published price. Everything else they publish, they publish the same way.

PlushCare costs $20 more than BioGlow Health — 16% more for the same molecule. Whether that buys anything is what the rest of this page is for.

Over twelve months that is about $1,548 at BioGlow Health against $1,788 at PlushCare — a difference of $240.

 BioGlow HealthPlushCare
Published price$129/mo$149/mo

Before you choose either

Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.

Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.

All head-to-head comparisons · The buyer’s guides